论文部分内容阅读
目的探讨经核苷类药物诊治乙肝炎后肝硬化的疗效。方法选取2009年5月~2013年5月开平市中心医院收治的乙肝后肝硬化者81例,随机均分为3组(n=27),即肝病1组、肝病2组和肝病3组。对肝病1组行拉米夫定诊治,对肝病2组行阿德福韦酯诊治,对肝病3组行恩替卡韦诊治。结果诊治1年之后,肝病1组、肝病2组及肝病3组的HBV之中的DNA承载量相比诊治前显著降低,差异有统计学意义(P<0.05);比较肝病1组、肝病2组、肝病3组间的疗效,肝病3组的HBeAg转变成阴性的概率、HBV的DNA承载量情况要比肝病1组、肝病2组好,差异有统计学意义(P<0.05)。3组全部无肾功能异常、血磷升高等不良事件。结论经核苷类药物诊治乙肝后肝硬化,可使机体承载的病毒量有效降低,效果突出。尤其恩替卡韦药物疗效更好,安全、可靠、效用高,且无不良反应,应当进一步予以临床推广。
Objective To investigate the efficacy of nucleoside drugs in the diagnosis and treatment of cirrhosis after hepatitis B Methods Eighty-one patients with post-cirrhosis of liver cirrhosis who were treated in Kaiping Central Hospital from May 2009 to May 2013 were randomly divided into three groups (n = 27), one group with liver disease, two with liver disease and three with liver disease. Lamivudine diagnosis and treatment of liver disease group 1, adefovir dipivoxil treatment of liver disease group 2, entecavir treatment of liver disease group 3. Results After one year of diagnosis and treatment, the DNA load of HBV in group 1, group 2 and group 3 was significantly lower than that before treatment (P <0.05). Comparing group 1 with liver disease, group 2 with liver disease There was significant difference between the two groups (P <0.05). The efficacy of HBeAg in the three groups of liver disease was negative. All 3 groups had no renal dysfunction, elevated serum phosphorus and other adverse events. Conclusion Nucleoside drugs in the diagnosis and treatment of cirrhosis of the liver can make the organism carry the effective reduction of the virus, the effect is outstanding. In particular, entecavir drug efficacy is better, safe, reliable, high utility, and no adverse reactions, should be further clinical promotion.